Skip to main content
logo
Apellis Pharmaceuticals, Inc. (APLS)
May 14, 2026 - APLS was delisted (reason: acquired by BIIB)
41.03
-0.03 (-0.07%)
Inactive · Last trade price on May 13, 2026

Apellis Pharmaceuticals Revenue by Segment

Period EndingDec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021
Product
689.38M690.21M689.03M696.78M709.95M657.44M580.05M490.56M
Product Growth
-2.90%4.99%18.79%42.04%93.83%165.87%249.90%434.47%
Collaboration License and Other
314.40M326.18M65.62M79.06M71.41M57.78M48.74M33.51M
Collaboration License and Other Growth
340.25%464.53%34.64%135.91%135.62%125.73%159.80%137.61%

Product Revenue by Segment

Period EndingDec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021
Syfovre
587.00M599.55M600.59M604.58M611.85M558.35M481.67M394.39M
Syfovre Growth
-4.06%7.38%24.69%53.30%122.26%246.84%462.03%2,048.08%
Empaveli
102.00M90.69M88.47M92.22M98.13M99.13M98.42M96.21M
Empaveli Growth
3.94%-8.52%-10.11%-4.15%7.79%14.81%22.81%30.91%